Neurolixis is an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system disorders including Parkinson's disease, Rett syndrome, depression and schizophrenia.

Neurolixis was founded in 2011 by highly experienced pharmaceutical industry professionals, with a world-class track record of CNS drug discovery, drug development, clinical trials, and company management.


Neurolixis Inc. has in-licensed early-stage clinical assets (Phase 1 and Phase 2) for repurposing in indications with unmet needs in psychiatric and neurological disorders. Read more...


Neurolixis has been awarded several research grants by private foundations, including the Michael J. Fox Foundation for Parkinson's research, the Rett Syndrome Research Trust and the International Rett Syndrome Foundation.  Read more...

Therapeutic focus

Neurolixis is developing clinical phase drugs targeting L-DOPA-induced dyskinesia in Parkinson's disease and breathing deficits in Rett syndrome, a devastating orphan disorder. Read more...